The US mid-cap sector is quietly undergoing a major overhaul this summer. I'm told that recent internal discussions across several niche leaders point to a rapid acceleration in strategic realignments and cross-sector partnerships. The monumental tie-up between Yelp and OpenAI is not just a technical upgrade for local search; it is a defining snapshot of how mid-cap players are reshaping their business models in 2026.

Yelp (YELP.US)

Yelp has been particularly active recently. I'm told that the company just pulled off a deal on July 23, 2026, that could fundamentally alter the local discovery landscape—a licensing agreement with OpenAI. Under this partnership, ChatGPT will leverage Yelp's massive trove of reviews and business data to enhance its chatbot capabilities. According to people familiar with the matter, Yelp's management views this as a pivotal AI rollout since the debut of "Yelp Assistant" in April. The company is set to report its Q2 earnings on August 6, where it is expected to share more commercial details on this alliance.

Medpace Holdings (MEDP.US)

Medpace has been on a tear this year, consistently outperforming its peers. The clinical CRO powerhouse reported its Q2 2026 results on July 23, delivering USD 707.3M in revenue, up 17.2% year-over-year. Even more telling is its net new business awards, which surged 28.2% to USD 795.7M. This signals that Medpace is aggressively capturing market share amid a recovering biotech funding environment. Several Wall Street analysts raised their price targets following the print, citing exceptionally strong demand as the company's backlog swelled past the USD 3B mark.

Trinity Capital (TRIN.US)

Trinity Capital is targeting a major upgrade to its institutional profile this year. The business development company officially moved its common stock from the Nasdaq to the New York Stock Exchange on July 27, 2026. This transition is often driven by a desire for deeper liquidity and a broader investor base. According to the company's latest figures, it secured USD 709M in new commitments during the second quarter, providing ample dry powder for its next phase of expansion.

Aureus Greenway Holdings (PUSA.US)

What started as a Florida-based golf club operator is now the center of a dramatic reverse merger. I've learned that Aureus Greenway is advancing its combination with drone maker Powerus. In a July 22 amendment to the deal, the contingent earnout shares issued to the target's shareholders were bumped up to 55M. People familiar with the matter suggest this transaction has attracted high-profile strategic investors, making it an intriguing backdoor listing to watch later this year.

Elite Express Holding (ETS.US)

The California-based last-mile delivery provider is navigating a transitional phase. While Elite Express posted Q2 revenue of USD 726,829 for the period ending May 31, 2026—a 15.3% year-over-year increase—its net loss widened substantially to USD 2.53M. I'm told this was primarily driven by a massive spike in R&D expenses as the company invests heavily in logistics tech. Management will need to prove that these upfront costs can eventually translate into bottom-line profitability.

Also

• Dolphin Entertainment (DLPN.US): In late June, the entertainment marketing firm teamed up with KYNETIC to launch Graviteur Studios, aiming to fund creator-led projects in the USD 1M to USD 10M range.
• Southwest Airlines (LUV.US): The low-cost airline giant has seen a slightly muted performance recently as the market awaits its capacity adjustment plans for the second half of 2026.
• AEVEX Corporation (AVEX.US): The government engineering solutions provider continues to steadily work through its defense and technology backlog, remaining relatively stable this year.
• Phaos Technology (POAS.US): Incorporated in the Cayman Islands, this advanced microscopy startup is trying to push its patented microsphere tech into broader biomedical applications.
• Montana Technologies (AIRJ.US): Public disclosures for this entity remain limited, and investors are largely in a wait-and-see mode regarding its technology commercialization path.

This article does not constitute investment advice.